BEAM THERAPEUTICS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 23.81 USD | -1.16% |
|
-2.10% | -12.53% |
| 05-07 | Beam Therapeutics Shares Fall After Q1 Revenue Misses Estimates | MT |
| 05-07 | Beam Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Sales 2024 * | 50.11M 3.93B | Sales 2025 * | 52.04M 4.08B | Capitalization | 1.88B 148B |
|---|---|---|---|---|---|
| Net income 2024 * | -402M -31.55B | Net income 2025 * | -432M -33.91B | EV / Sales 2024 * | 21.8 x |
| Net cash position 2024 * | 786M 61.71B | Net cash position 2025 * | 376M 29.52B | EV / Sales 2025 * | 28.9 x |
| P/E ratio 2024 * |
-5.04
x | P/E ratio 2025 * |
-5.04
x | Employees | 346 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.48% |
More Fundamentals
* Assessed data
More news
Latest transcript on Beam Therapeutics Inc.
More recommendations
More press releases
More news
| 1 day | -1.16% | ||
| 1 week | -2.10% | ||
| Current month | -0.04% | ||
| 1 month | +9.52% | ||
| 3 months | -40.24% | ||
| 6 months | -19.48% | ||
| Current year | -12.53% |
1 week
22.65
24.69
1 month
21.1826.15
Current year
20.8449.50
1 year
16.9549.50
3 years
16.95138.52
5 years
13.00138.52
10 years
13.00138.52
| Managers | Title | Age | Since |
|---|---|---|---|
John Evans
CEO | Chief Executive Officer | 46 | 31/12/16 |
| President | 55 | 31/01/18 | |
| Director of Finance/CFO | 47 | 31/07/19 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Graham Cooper
BRD | Director/Board Member | 54 | 09/10/19 |
John Maraganore
BRD | Director/Board Member | 60 | 04/11/21 |
Mark Fishman
BRD | Director/Board Member | 73 | 30/04/18 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 8.03% | 2 M€ | -25.75% | ||
| 4.10% | 0 M€ | -.--% | - | |
| 4.00% | 1 M€ | -.--% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 31/05/24 | 23.82 | -1.12% | 948,776 |
| 30/05/24 | 24.09 | +1.73% | 1,224,381 |
| 29/05/24 | 23.68 | -2.23% | 845,182 |
| 28/05/24 | 24.22 | -0.41% | 755,403 |
| 24/05/24 | 24.32 | +1.29% | 385,361 |
Delayed Quote Nasdaq, May 31, 2024 at 09:00 pm
More quotes
Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. The Company's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases, as well as immunology/oncology. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302, BEAM-301 and BEAM-201. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents. BEAM-201 is an anti-CD7 CAR-T product candidate.
Calendar
05/06/2024
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
23.82
USD
Average target price
48.38
USD
Spread / Average Target
+103.13%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -12.53% | 1.88B | |
| +43.36% | 54.63B | |
| -5.31% | 39.92B | |
| +14.75% | 26.86B | |
| -12.56% | 26.22B | |
| -22.45% | 18.78B | |
| +25.12% | 12.21B | |
| +0.04% | 12.16B | |
| +26.04% | 11.94B | |
| -11.83% | 10.74B |
- Stock Market
- Equities
- BEAM Stock
